Trials / Completed
CompletedNCT03768323
Airtime Incentive Amounts to Improve Interactive Voice Response Surveys in Bangladesh and Uganda
A Randomized Controlled Trial of Varying Airtime Incentive Amounts to Improve Interactive Voice Response (IVR) Survey Performance in Bangladesh and Uganda
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 4,233 (actual)
- Sponsor
- Johns Hopkins Bloomberg School of Public Health · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This study evaluates the effect of two different airtime incentive amounts on interactive voice response (IVR) survey cooperation, response, refusal, and contact rates, as compared to control group, in Bangladesh and Uganda.
Detailed description
Using random digit dialing sampling techniques, the investigators randomized random digit dialed (RDD) participants to one of three airtime incentive amounts contingent on them completing the noncommunicable disease risk factor survey. This mobile phone survey was sent as an interactive voice response (IVR). In IVR surveys, participants use their touch tone key pad to answer pre-recorded questions. (i.e. If you are male, press 1; If you are female, press 2). This study was conducted in both Bangladesh and Uganda
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | 1X airtime incentive | an incentive given in the form of airtime to motivate participants to complete the survey. Participants were given 50 Bangladeshi Taka ($0.60 USD) or 5000 Ugandan Shillings (UGX; $1.35 USD as of April 3, 2018) worth of airtime for completing the survey |
| OTHER | 2X airtime incentive | an incentive given in the form of airtime to motivate participants to complete the survey. Participants were given 100 Bangladeshi Taka ($1.20 USD) or 10000 UGX ($2.70 USD) worth of airtime for completing the survey |
Timeline
- Start date
- 2017-03-26
- Primary completion
- 2017-07-14
- Completion
- 2017-07-14
- First posted
- 2018-12-07
- Last updated
- 2018-12-10
Locations
2 sites across 2 countries: Bangladesh, Uganda
Source: ClinicalTrials.gov record NCT03768323. Inclusion in this directory is not an endorsement.